ArticleAntimicrobial agents and chemotherapy2011
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.The Journal of antimicrobial chemotherapy · 2017Trial
- In Vitro Antifungal Drug Susceptibility of Feline Sporothrix schenckii Complex Isolates, Thailand, 2023-2025.Emerging infectious diseases · 2026Article
- Algal extract as a key protective agent: Jania rubens-enriched PVA/CMC coatings for postharvest onion disease control.BMC plant biology · 2026Article
- Mycological Survey of Fungal Carriage in Cats and Their Owners: Analysis of Species Diversity and Antifungal Susceptibility.Journal of fungi (Basel, Switzerland) · 2026Article
- Pamamycin Disrupts the Cell Envelope and Mitochondrial Potential to InhibitFoods (Basel, Switzerland) · 2026Article
- An invasiveMedical mycology case reports · 2026Article
- Antifungal susceptibility and genomic profile associated with biosynthetic gene clusters of bovine mastitis-derivedFrontiers in microbiology · 2026Article
- Pulmonary and ocular aspergillosis with reduced susceptibility to amphotericin B: A Malaysian case series.IDCases · 2026Article
- Review
- Synergistic Antifungal Activity of PIT and ITZ Against Varied Aspergillus Species via Affecting The Ergosterol Content and Intracellular Drug Retention.Current microbiology · 2025Article
- Chitosan-silver nanocomposites: promising alternatives for combating azole-resistantFrontiers in cellular and infection microbiology · 2025Article
- Commercial Methods for Antifungal Susceptibility Testing of Saprophytic Molds: Can They Be Used to Detect Resistance?Journal of fungi (Basel, Switzerland) · 2024Review
- Species Distribution and Antifungal Susceptibilities ofPathogens (Basel, Switzerland) · 2023Article
- Article
- Transcriptomics-based investigation of molecular mechanisms underlying synergistic antimicrobial effects of AgNPs and Domiphen on the human fungal pathogenFrontiers in microbiology · 2023Article
- Multicenter Study of Susceptibility of Aspergillus Species Isolated from Iranian University Hospitals to Seven Antifungal Agents.Microbiology spectrum · 2022Article
- Aspergillus tubingensis Endocarditis: A Case Report and Review of the Literature.Mycopathologia · 2022Review
- Article
- Effective Inhibition of Invasive Pulmonary Aspergillosis by Silver Nanoparticles Biosynthesized withNanomaterials (Basel, Switzerland) · 2021Article
- Cyclopeptide Derivatives from the Sponge-Derived FungusMarine drugs · 2021Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although clinical breakpoints have not been established for mold testing, epidemiological cutoff values (ECVs) are available for Aspergillus spp. versus the triazoles and caspofungin. Wild-type (WT) MIC distributions (organisms in a species-drug combination with no acquired resistance mechanisms) were defined in order to establish ECVs for six Aspergillus spp. and amphotericin B. Two sets (CLSI/EUCAST broth microdilution) of available MICs were evaluated: those for A. fumigatus (3,988/833), A. flavus (793/194), A. nidulans (184/69), A. niger (673/140), A. terreus (545/266), and A. versicolor (135/22). Three sets of data were analyzed: (i) CLSI data gathered in eight independent laboratories in Canada, Europe, and the United States; (ii) EUCAST data from a single laboratory; and (iii) the combined CLSI and EUCAST data. ECVs, expressed in μg/ml, that captured 95%, 97.5%, and 99% of the modeled wild-type population (CLSI and combined data) were as follows: for A. fumigatus, 2, 2, and 4; for A. flavus, 2, 4, and 4; for A. nidulans, 4, 4, and 4; for A. niger, 2, 2, and 2; for A. terreus, 4, 4, and 8; and for A. versicolor, 2, 2, and 2. Similar to the case for the triazoles and caspofungin, amphotericin B ECVs may aid in the detection of strains with acquired mechanisms of resistance to this agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.